Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data
Buprenorphine-naloxone might be superior to extended-release naltrexone in real-world settings where the majority of people struggle to remain on medications for opioid use disorder. Buprenorphine-naloxone initiators had a lower risk of treatment interruption than extended-release naltrexone initiators in an observational emulation, but similar risks in a randomized controlled trial, although confidence intervals were wide. Trial participation, study size and residual confounding may explain these differences.
Authors
- Benjamin J. Bovell-Ammon (ORCID: https://orcid.org/0000-0003-4564-6705)
- Patricia Novo
- Sara Lodi (ORCID: https://orcid.org/0000-0002-9419-7830)
- Marc R. Larochelle (ORCID: https://orcid.org/0000-0001-7344-1200)
- Joshua D. Lee (ORCID: https://orcid.org/0000-0003-3161-2950)
- Alexander Yale Walley (ORCID: https://orcid.org/0000-0002-8158-4882)
- Dana Bernson (ORCID: https://orcid.org/0000-0003-1510-4489)
- Jane M. Liebschutz (ORCID: https://orcid.org/0000-0003-3492-1521)
- Heather Hsu (ORCID: https://orcid.org/0000-0002-5863-1804)
- John Rotrosen (ORCID: https://orcid.org/0000-0002-0283-5576)
- Paul J. Christine (ORCID: https://orcid.org/0000-0003-1707-0761)
- Shapei Yan (ORCID: https://orcid.org/0000-0001-6012-6850)
Institutions
- Boston University (US)
- Boston Medical Center (US)
- Massachusetts Department of Public Health (US)
- University of Pittsburgh (US)
- New York University (US)
Publication Details
- Journal
- Addiction
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1111/add.70040
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute on Drug Abuse